Overview Dividends

(EW) Edwards Lifesciences - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US28176E1082

Valve Replacement, Valve Repair, Surgical Valves

EW EPS (Earnings per Share)

EPS Growth (3Y CAGR): -58.19%
EPS Trend (3Y Correlation): -44.6%

EW Revenue

Revenue Growth (3Y CAGR): 5.60%
Revenue Trend (3Y Correlation): 49.1%

Description: EW Edwards Lifesciences September 29, 2025

Edwards Lifesciences (NYSE:EW) develops and sells minimally invasive cardiovascular devices, including the transcatheter aortic valve replacement (TAVR) SAPIEN system, the mitral/tricuspid repair platforms PASCAL PRECISION and Cardioband, and a suite of surgical structural-heart products under the INSPIRIS brand such as RESILIA tissue valves and the KONECT conduit. The firm markets its portfolio worldwide through a direct sales force and independent distributors, and has been operating since 1958 from its Irvine, California headquarters.

Key recent metrics: FY 2023 revenue reached approximately $5.2 billion, driven by a 12 % year-over-year increase in TAVR sales, which now represent roughly 45 % of the U.S. TAVR market share. The company’s pipeline includes next-generation RESILIA tissue technologies that aim to extend valve durability, a critical factor as the aging global population (projected to exceed 1.5 billion people over 65 by 2030) fuels demand for less invasive cardiac interventions. A material economic driver is Medicare’s evolving reimbursement policy for TAVR, which can materially affect pricing power and adoption rates.

For a deeper, data-rich analysis of EW’s valuation dynamics, consider exploring the detailed metrics and scenario models available on ValueRay.

EW Stock Overview

Market Cap in USD	43,821m
Sub-Industry	Health Care Equipment
IPO / Inception	2000-03-27

EW Stock Ratings

Growth Rating	15.9%
Fundamental	69.5%
Dividend Rating	-
Return 12m vs S&P 500	-8.59%
Analyst Rating	3.69 of 5

EW Dividends

Currently no dividends paid

EW Growth Ratios

Growth Correlation 3m	-71%
Growth Correlation 12m	72.7%
Growth Correlation 5y	-63.2%
CAGR 5y	2.42%
CAGR/Max DD 3y (Calmar Ratio)	0.06
CAGR/Mean DD 3y (Pain Ratio)	0.15
Sharpe Ratio 12m	-0.44
Alpha	-8.23
Beta	1.047
Volatility	27.81%
Current Volume	3165.7k
Average Volume 20d	3792.2k
Stop Loss	73.8 (-3%)
Signal	-0.83

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (4.14b TTM) > 0 and > 6% of Revenue (6% = 341.1m TTM)

FCFTA 0.07 (>2.0%) and ΔFCFTA 2.15pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 90.98% (prev 63.13%; Δ 27.85pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.09 (>3.0%) and CFO 1.20b <= Net Income 4.14b (YES >=105%, WARN >=100%)

Net Debt (-2.57b) to EBITDA (1.78b) ratio: -1.44 <= 3.0 (WARN <= 3.5)

Current Ratio 4.68 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (587.9m) change vs 12m ago -2.71% (target <= -2.0% for YES)

Gross Margin 78.90% (prev 78.75%; Δ 0.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 48.20% (prev 51.74%; Δ -3.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 82.39 (EBITDA TTM 1.78b / Interest Expense TTM 19.8m) >= 6 (WARN >= 3)

Altman Z'' 11.99

(A) 0.38 = (Total Current Assets 6.58b - Total Current Liabilities 1.40b) / Total Assets 13.49b

(B) 1.03 = Retained Earnings (Balance) 13.86b / Total Assets 13.49b

warn (B) unusual magnitude: 1.03 — check mapping/units

(D) 4.94 = Book Value of Equity 14.25b / Total Liabilities 2.88b

Total Rating: 11.99 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 69.52

1. Piotroski 6.0pt = 1.0

2. FCF Yield 2.50% = 1.25

3. FCF Margin 17.76% = 4.44

4. Debt/Equity 0.07 = 2.50

5. Debt/Ebitda -1.44 = 2.50

6. ROIC - WACC (= 3.10)% = 3.88

7. RoE 41.22% = 2.50

8. Rev. Trend 49.13% = 3.68

9. EPS Trend -44.61% = -2.23

What is the price of EW shares?

As of October 26, 2025, the stock is trading at USD 76.10 with a total of 3,165,667 shares traded.
Over the past week, the price has changed by +1.96%, over one month by +1.93%, over three months by +0.40% and over the past year by +8.17%.

Is Edwards Lifesciences a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Edwards Lifesciences (NYSE:EW) is currently (October 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 69.52 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EW is around 67.47 USD . This means that EW is currently overvalued and has a potential downside of -11.34%.

Is EW a buy, sell or hold?

Edwards Lifesciences has received a consensus analysts rating of 3.69. Therefor, it is recommend to hold EW.

Strong Buy: 10
Buy: 4
Hold: 17
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the EW price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	87.1	14.5%
Analysts Target Price	87.1	14.5%
ValueRay Target Price	76.1	-0%

EW Fundamental Data Overview October 20, 2025

Market Cap USD = 43.82b (43.82b USD * 1.0 USD.USD)
P/E Trailing = 31.2301
P/E Forward = 27.8552
P/S = 7.7081
P/B = 4.2674
P/EG = 4.1293
Beta = 1.047
Revenue TTM = 5.69b USD
EBIT TTM = 1.63b USD
EBITDA TTM = 1.78b USD
Long Term Debt = 598.0m USD (from longTermDebt, last quarter)
Short Term Debt = 25.9m USD (from shortTermDebt, last quarter)
Debt = 702.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.57b USD (from netDebt column, last quarter)
Enterprise Value = 40.46b USD (43.82b + Debt 702.6m - CCE 4.06b)
Interest Coverage Ratio = 82.39 (Ebit TTM 1.63b / Interest Expense TTM 19.8m)
FCF Yield = 2.50% (FCF TTM 1.01b / Enterprise Value 40.46b)
FCF Margin = 17.76% (FCF TTM 1.01b / Revenue TTM 5.69b)
Net Margin = 72.90% (Net Income TTM 4.14b / Revenue TTM 5.69b)
Gross Margin = 78.90% ((Revenue TTM 5.69b - Cost of Revenue TTM 1.20b) / Revenue TTM)
Gross Margin QoQ = 77.64% (prev 78.65%)
Tobins Q-Ratio = 3.00 (Enterprise Value 40.46b / Total Assets 13.49b)
Interest Expense / Debt = 2.82% (Interest Expense 19.8m / Debt 702.6m)
Taxrate = 16.07% (64.3m / 400.2m)
NOPAT = 1.37b (EBIT 1.63b * (1 - 16.07%))
Current Ratio = 4.68 (Total Current Assets 6.58b / Total Current Liabilities 1.40b)
Debt / Equity = 0.07 (Debt 702.6m / totalStockholderEquity, last quarter 10.55b)
Debt / EBITDA = -1.44 (Net Debt -2.57b / EBITDA 1.78b)
Debt / FCF = -2.55 (Net Debt -2.57b / FCF TTM 1.01b)
Total Stockholder Equity = 10.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 30.72% (Net Income 4.14b / Total Assets 13.49b)
RoE = 41.22% (Net Income TTM 4.14b / Total Stockholder Equity 10.05b)
RoCE = 15.31% (EBIT 1.63b / Capital Employed (Equity 10.05b + L.T.Debt 598.0m))
RoIC = 12.85% (NOPAT 1.37b / Invested Capital 10.65b)
WACC = 9.75% (E(43.82b)/V(44.52b) * Re(9.87%) + D(702.6m)/V(44.52b) * Rd(2.82%) * (1-Tc(0.16)))
Discount Rate = 9.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.58%
[DCF Debug] Terminal Value 66.25% ; FCFE base≈821.2m ; Y1≈623.1m ; Y5≈380.6m
Fair Price DCF = 9.16 (DCF Value 5.38b / Shares Outstanding 587.1m; 5y FCF grow -28.62% → 3.0% )
EPS Correlation: -44.61 | EPS CAGR: -58.19% | SUE: -4.0 | # QB: 0
Revenue Correlation: 49.13 | Revenue CAGR: 5.60% | SUE: 0.29 | # QB: 0

Additional Sources for EW Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle